Diazoxide
Proglycem (diazoxide) is a small molecule pharmaceutical. Diazoxide was first approved as Hyperstat on 1982-01-01. It is used to treat hypoglycemia and malignant hypertension in the USA. It is known to target ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, and nicotinamide phosphoribosyltransferase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Proglycem (generic drugs available since 2019-12-20, discontinued: Hyperstat)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diazoxide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROGLYCEM | Teva | N-017453 RX | 1982-01-01 | 1 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypoglycemia | HP_0001943 | D007003 | E16.2 |
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DA: Thiazide derivatives acting on arteriolar smooth muscle
— C02DA01: Diazoxide
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AH: Drugs for treatment of hypoglycemia
— V03AH01: Diazoxide
HCPCS
Code | Description |
|---|---|
| J1730 | Injection, diazoxide, up to 300 mg |
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | 3 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | — | 1 | — | 4 |
| Glucose metabolism disorders | D044882 | — | 3 | — | 1 | — | 4 | ||
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | 1 | 1 | — | 2 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertriglyceridemia | D015228 | EFO_0004211 | 3 | 2 | — | — | — | 5 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 4 | — | — | — | 4 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 1 | 1 | — | — | — | 2 |
| Dyslipidemias | D050171 | HP_0003119 | — | 1 | — | — | — | 1 | |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | 1 | — | — | — | 1 |
| Depression | D003863 | F33.9 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial stunning | D017682 | 1 | — | — | — | — | 1 | ||
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Reperfusion injury | D015427 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIAZOXIDE |
| INN | diazoxide |
| Description | Diazoxide is a benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. It has a role as an antihypertensive agent, a sodium channel blocker, a vasodilator agent, a K-ATP channel agonist, a beta-adrenergic agonist, a cardiotonic drug, a bronchodilator agent, a sympathomimetic agent and a diuretic. It is a benzothiadiazine, a sulfone and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |
Target
Agency Approved
No data
Alternate
KCNJ8
KCNJ8
KCNJ11
KCNJ11
NAMPT
NAMPT
Organism
Homo sapiens
Gene name
KCNJ8
Gene synonyms
NCBI Gene ID
Protein name
ATP-sensitive inward rectifier potassium channel 8
Protein synonyms
Inward rectifier K(+) channel Kir6.1, inwardly rectifying potassium channel KIR6.1, Potassium channel, inwardly rectifying subfamily J member 8, potassium voltage-gated channel subfamily J member 8, uKATP-1
Uniprot ID
Mouse ortholog
Kcnj8 (16523)
ATP-sensitive inward rectifier potassium channel 8 (P97794)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,834 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,472 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more